These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22191123)

  • 21. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib: a therapeutic resource for the veterinary oncologist?
    Reisman SA
    Vet J; 2013 Dec; 198(3):543-4. PubMed ID: 24210275
    [No Abstract]   [Full Text] [Related]  

  • 23. Proteasome inhibitors.
    Wilkes G
    Oncology (Williston Park); 2007 Apr; 21(4 Suppl):48. PubMed ID: 17508503
    [No Abstract]   [Full Text] [Related]  

  • 24. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
    Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.
    Hiroi T; Deming CB; Zhao H; Hansen BS; Arkenbout EK; Myers TJ; McDevitt MA; Rade JJ
    Arterioscler Thromb Vasc Biol; 2009 Oct; 29(10):1587-93. PubMed ID: 19661484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteasome inhibitors as therapeutics.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
    Fennell DA; Chacko A; Mutti L
    Oncogene; 2008 Feb; 27(9):1189-97. PubMed ID: 17828309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Progress in the study of proteasome inhibitor inducing hepatic stellate cell apoptosis].
    Zhang YJ; Fang BW
    Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):878-80. PubMed ID: 18073087
    [No Abstract]   [Full Text] [Related]  

  • 31. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Pekol T; Daniels JS; Labutti J; Parsons I; Nix D; Baronas E; Hsieh F; Gan LS; Miwa G
    Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.
    Cvek B
    Hum Reprod; 2009 Nov; 24(11):2967; author reply 2967-8. PubMed ID: 19687055
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
    Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
    Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
    Gräwert MA; Groll M
    Chem Commun (Camb); 2012 Feb; 48(10):1364-78. PubMed ID: 22039589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
    Crawford LJ; Walker B; Ovaa H; Chauhan D; Anderson KC; Morris TC; Irvine AE
    Cancer Res; 2006 Jun; 66(12):6379-86. PubMed ID: 16778216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
    Rukavitsyn OA
    Ter Arkh; 2006; 78(10):40-4. PubMed ID: 17180936
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.